Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):720-723. doi: 10.1016/j.clml.2021.07.019. Epub 2021 Jul 29.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Azacitidine* / pharmacology
  • Azacitidine* / therapeutic use
  • Cytarabine* / pharmacology
  • Cytarabine* / therapeutic use
  • Female
  • Granulocyte Colony-Stimulating Factor* / pharmacology
  • Granulocyte Colony-Stimulating Factor* / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute
  • Male
  • Middle Aged
  • Vidarabine* / analogs & derivatives
  • Vidarabine* / pharmacology
  • Vidarabine* / therapeutic use
  • Young Adult

Substances

  • Azacitidine
  • Cytarabine
  • fludarabine
  • Granulocyte Colony-Stimulating Factor
  • Vidarabine